JP2023520506A5 - - Google Patents

Info

Publication number
JP2023520506A5
JP2023520506A5 JP2022560168A JP2022560168A JP2023520506A5 JP 2023520506 A5 JP2023520506 A5 JP 2023520506A5 JP 2022560168 A JP2022560168 A JP 2022560168A JP 2022560168 A JP2022560168 A JP 2022560168A JP 2023520506 A5 JP2023520506 A5 JP 2023520506A5
Authority
JP
Japan
Prior art keywords
approximately
nucleic acid
pharmaceutical composition
nanoparticle
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022560168A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023520506A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/025222 external-priority patent/WO2021202772A1/en
Publication of JP2023520506A publication Critical patent/JP2023520506A/ja
Publication of JP2023520506A5 publication Critical patent/JP2023520506A5/ja
Pending legal-status Critical Current

Links

JP2022560168A 2020-04-01 2021-03-31 Sars-cov-2に対する多層rnaナノ粒子ワクチン Pending JP2023520506A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063003766P 2020-04-01 2020-04-01
US63/003,766 2020-04-01
US202063022999P 2020-05-11 2020-05-11
US63/022,999 2020-05-11
US202063128600P 2020-12-21 2020-12-21
US63/128,600 2020-12-21
PCT/US2021/025222 WO2021202772A1 (en) 2020-04-01 2021-03-31 Multilamellar rna nanoparticle vaccine against sars-cov-2

Publications (2)

Publication Number Publication Date
JP2023520506A JP2023520506A (ja) 2023-05-17
JP2023520506A5 true JP2023520506A5 (cg-RX-API-DMAC7.html) 2024-03-22

Family

ID=75625672

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022560168A Pending JP2023520506A (ja) 2020-04-01 2021-03-31 Sars-cov-2に対する多層rnaナノ粒子ワクチン

Country Status (6)

Country Link
US (1) US20230226169A1 (cg-RX-API-DMAC7.html)
EP (1) EP4126030A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023520506A (cg-RX-API-DMAC7.html)
AU (1) AU2021247163A1 (cg-RX-API-DMAC7.html)
CA (1) CA3174187A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021202772A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7783628B2 (ja) * 2019-07-19 2025-12-10 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 多層rnaナノ粒子
CN118490818A (zh) 2020-04-22 2024-08-16 生物技术欧洲股份公司 冠状病毒疫苗
US20230314432A1 (en) * 2020-07-10 2023-10-05 Covid Diagnostics Ltd. Compositions, methods, and systems for detecting immune response
US20220042117A1 (en) * 2020-08-06 2022-02-10 Roche Molecular Systems, Inc. COMPOSITIONS AND METHODS FOR THE SIMULTANEOUS DETECTION OF INFLUENZA A, INFLUENZA B, AND SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
IL303434A (en) * 2020-12-07 2023-08-01 Tufts College Lipidoid preparations and methods of using them
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
WO2024010686A2 (en) * 2022-06-20 2024-01-11 The Trustees Of Columbia University In The City Of New York Vaccine tissue assays
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
WO2025089649A1 (ko) * 2023-10-26 2025-05-01 주식회사 차백신연구소 양이온성 리포좀을 포함하는 핵산 전달용 조성물 및 그의 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
KR20220038506A (ko) 2009-06-10 2022-03-28 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
WO2011149733A2 (en) 2010-05-24 2011-12-01 Merck Sharp & Dohme Corp. Novel amino alcohol cationic lipids for oligonucleotide delivery
DK2575767T3 (en) 2010-06-04 2017-03-13 Sirna Therapeutics Inc HOWEVER UNKNOWN LOW MOLECULAR CATIONIC LIPIDS TO PROCESS OIGONUCLEOTIDES
US11058762B2 (en) * 2011-07-06 2021-07-13 Glaxosmithkline Biologicals Sa Immunogenic compositions and uses thereof
EA201492055A1 (ru) * 2012-06-08 2015-11-30 Шир Хьюман Дженетик Терапис, Инк. ИНГАЛЯЦИОННАЯ ДОСТАВКА мРНК В НЕЛЕГОЧНЫЕ КЛЕТКИ-МИШЕНИ
CN107073028A (zh) * 2013-12-13 2017-08-18 南洋理工大学 多层纳米颗粒及其制作方法和使用方法
BR112020004351A2 (pt) * 2017-10-19 2020-09-08 Curevac Ag moléculas de ácido nucleico artificial
US10979132B2 (en) * 2018-08-10 2021-04-13 Qualcomm Incorporated Organization of inter-relay discovery reference signals
JP7783628B2 (ja) * 2019-07-19 2025-12-10 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 多層rnaナノ粒子
US12194089B2 (en) * 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine

Similar Documents

Publication Publication Date Title
US20220370370A1 (en) Lipid nanoparticles comprising lipophilic anti-inflammatory agents and methods of use thereof
CN114716355B (zh) 一种脂质化合物、包含其的组合物及应用
Purohit et al. Interaction of cationic partial dendrimers with charged and neutral liposomes
CN116672316B (zh) 一种核酸-脂质纳米颗粒冻干制剂及其制备方法
CN110522918A (zh) 靶向元件及其制备方法和运用
CN102336802B (zh) 甘草次酸修饰脂质、肝靶向脂质体、胶束及复合物和制法
JP2023512707A5 (cg-RX-API-DMAC7.html)
CN1237102A (zh) 脂质体
Rodriguez-Gascon et al. Vaginal gene therapy
CN114404391B (zh) 一种纳米粒及其制备方法和用途
JP2025138644A5 (cg-RX-API-DMAC7.html)
CN118203546A (zh) 生产脂质体的方法
CN116236565B (zh) 适合于肌注给药的核酸-脂质纳米颗粒、制剂及其应用
JP2014506918A (ja) 抗腫瘍活性物質を含むリポソーム製剤、その調製のための方法、及び、それを含む医薬組成物
PL211710B1 (pl) Zastosowanie lipozomów zawierających związek o wzorze (II) ,jako nośnika do transportu leków lub substancji posiadających aktywność kosmetyczną
CN118267376A (zh) 一种核酸递送载体及其制备方法和用途
CN115087437A (zh) 脂质组合物及其用于将治疗活性剂递送至内皮的用途
Shanmugam et al. Nanostructured self assembled lipid materials for drug delivery and tissue engineering
CN114848831A (zh) 包裹型纳米制剂及其载体的制备方法和应用
WO2024205498A1 (en) Nanoparticle-based nucleic acid delivery system
CN116549667B (zh) 一种pas修饰的脂质纳米粒、包含其的药物制剂,及其制备方法和用途
CN118178664A (zh) 一种用于核酸递送的脂质材料及其用途
CN120754284B (zh) 一种用于肝脏靶向联合递送CRISPR-Cas9系统和单链DNA修复模板的脂质纳米颗粒
CN120694948A (zh) 一种纳米硒修饰脂质体及其制备方法与应用
TW202530174A (zh) 用於遞送的脂質化合物及脂質奈米顆粒